TKI biotech lays out plans to raise about $125M in IPO; Hookipa sets terms for up­sized $100M IPO

→ San Diego-based Turn­ing Point Ther­a­peu­tics has laid out terms for its IPO, plan­ning to sell 7.4 mil­lion shares at a range of $16 to $18 a share. Re­nais­sance Cap­i­tal re­ports that in­sid­ers ex­pect to take about 40% of a to­tal of around $125 mil­lion, which would give the on­col­o­gy biotech a val­u­a­tion of more than $500 mil­lion. They’ll sell shares un­der the $TP­TX sym­bol. The biotech is de­vel­op­ing a pipeline of ty­ro­sine ki­nase in­hibitors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.